<code id='F79215AB2C'></code><style id='F79215AB2C'></style>
    • <acronym id='F79215AB2C'></acronym>
      <center id='F79215AB2C'><center id='F79215AB2C'><tfoot id='F79215AB2C'></tfoot></center><abbr id='F79215AB2C'><dir id='F79215AB2C'><tfoot id='F79215AB2C'></tfoot><noframes id='F79215AB2C'>

    • <optgroup id='F79215AB2C'><strike id='F79215AB2C'><sup id='F79215AB2C'></sup></strike><code id='F79215AB2C'></code></optgroup>
        1. <b id='F79215AB2C'><label id='F79215AB2C'><select id='F79215AB2C'><dt id='F79215AB2C'><span id='F79215AB2C'></span></dt></select></label></b><u id='F79215AB2C'></u>
          <i id='F79215AB2C'><strike id='F79215AB2C'><tt id='F79215AB2C'><pre id='F79215AB2C'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:knowledge    - browse:37
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia